Asia Pacific Blood Cancer Diagnostics Market Size & Outlook
- Clinical Diagnostics
- Cancer Diagnostics
- Blood Cancer Diagnostics Market Outlook
- Cancer Diagnostics
Global Market
Related Markets
Ask a question about the blood cancer diagnostics market
Asia Pacific blood cancer diagnostics market highlights
- The Asia Pacific blood cancer diagnostics market generated a revenue of USD 2,636.6 million in 2024.
- The market is expected to grow at a CAGR of 8.3% from 2025 to 2030.
- In terms of segment, assay kits and reagents was the largest revenue generating product in 2024.
- Assay Kits and Reagents is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 2,636.6 million |
| Market revenue in 2030 | USD 4,265.2 million |
| Growth rate | 8.3% (CAGR from 2025 to 2030) |
| Largest segment | Assay kits and reagents |
| Fastest growing segment | Assay Kits and Reagents |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Assay Kits and Reagents |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 24.4% of the global blood cancer diagnostics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 4,265.2 million by 2030.
Blood cancer is a significant health concern in Asia, with the International Agency for Research on Cancer (IARC) reporting over 1 million new cases of cancer in Southeast Asia in 2020, and this number is expected to rise to 11.5 million by 2030.
The blood cancer diagnostics market in the region is predicted to experience growth in the future due to rising demand for treatment options and the increasing incidence of various lymphoma types during the forecast period. Key market players are actively involved in R&D, resulting in a robust pipeline of potential treatments.
For instance, Kura Oncology's ongoing clinical trial for tipifarnib, a pipeline candidate being investigated for treating peripheral T-cell lymphoma, demonstrates the company's commitment to advancing innovative therapies for patients.
No credit card required*
Publish Date: Mar 21, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Blood Cancer Diagnostics Market Scope
Blood Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Quest Diagnostics Inc | View profile | 48,000 | 500 Plaza Drive, Secaucus, NJ, United States, 07094 | www.questdiagnostics.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Bio-Techne Corp | View profile | 3,050 | 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 | www.bio-techne.com |
| Sophia Genetics SA | View profile | 449 | La Pièce 12, Rolle, Switzerland, CH-1180 | www.sophiagenetics.com |
| Adaptive Biotechnologies | View profile | 501-1000 | Seattle, Washington, United States, North America | adaptivebiotech.com |
| Danaher Corporation | View profile | - | - | - |
| QIAGEN | View profile | - | - | - |
| Abbott | View profile | - | - | - |
| Invivoscribe, Inc. | View profile | 251-500 | San Diego, California, United States, North America | www.invivoscribe.com |
Asia Pacific Blood Cancer Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Blood Cancer Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Assay Kits And Reagents was the largest segment with a revenue share of 72.71% in 2024.
Horizon Databook has segmented the Asia Pacific blood cancer diagnostics market based on instruments, assay kits and reagents covering the revenue growth of each sub-segment from 2018 to 2030.
Blood cancer is a significant health concern in Asia, with the International Agency for Research on Cancer (IARC) reporting over 1 million new cases of cancer in Southeast Asia in 2020, and this number is expected to rise to 11.5 million by 2030.
The blood cancer diagnostics market in the region is predicted to experience growth in the future due to rising demand for treatment options and the increasing incidence of various lymphoma types during the forecast period. Key market players are actively involved in R&D, resulting in a robust pipeline of potential treatments.
For instance, Kura Oncology's ongoing clinical trial for tipifarnib, a pipeline candidate being investigated for treating peripheral T-cell lymphoma, demonstrates the company's commitment to advancing innovative therapies for patients.
- Asia Pacific Blood Cancer Diagnostics Market Product Outlook (Revenue, USD Million , 2018-2030)
- Instruments
- Assay Kits and Reagents
- Asia Pacific Blood Cancer Diagnostics Market Test Outlook (Revenue, USD Million , 2018-2030)
- Blood Tests
- Imaging Tests
- Biopsy
- Molecular Test
- Asia Pacific Blood Cancer Diagnostics Market Enduse Outlook (Revenue, USD Million , 2018-2030)
- Hospitals and Clinics
- Diagnostic Labs
- Research Institutes
Reasons to subscribe to Blood Cancer Diagnostics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Blood Cancer Diagnostics Market Outlook databook
- Our clientele includes a mix of Blood Cancer Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Blood Cancer Diagnostics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Blood Cancer Diagnostics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Asia Pacific Blood Cancer Diagnostics Market, 2018-2030 (US$M)
Asia Pacific blood cancer diagnostics market statistics, by product, 2018-2030 (US$M)
